Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CLDN6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLDN6 Full-Length Lentivirus HEK293 Expressed, >10^8 TU/ml. Sequence Verified, preserves native 4-TM conformation. |
View CLDN6 Products |
| Gene Delivery | CLDN6 Promise-ORF Lentivirus Codon-optimized for high surface expression in CHO/K562 cells. |
View CLDN6 Products |
| Benchmark Ab | Anti-CLDN6 (Sequence of BNT211 CAR-scFv) Recombinant positive control, Endotoxin <1 EU/ug. |
View CLDN6 Products |
| Validator | CLDN6 siRNA Set Three target-specific sequences for knockdown specificity verification. |
View CLDN6 Products |
| Off-Target Control | CLDN9 (Closest Homolog) Full-length Lentivirus for specificity counter-screening (80% homology). |
View CLDN9 Products |
| Family Control | CLDN3 Tight junction protein for claudin family selectivity assays. |
View CLDN3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CLDN9 Homology Cross-reactivity (Extracellular Loop 1: 4 AA difference) | Human CLDN6 vs CLDN9 Ortholog Lentivirus Pair (Sequence verified by Mass Spec, >95% purity) |
| Species Translation (Human/Cyno/Mouse Toxicology) | Cross-species Lentivirus Panel (Human, Cyno, Mouse CLDN6 ORF) for preclinical safety |
| ADC Internalization Efficiency Quantification | High-expression Stable Cell Lines (Lentivirus-transduced HEK293) for pH-sensitive dye uptake assays |
| False Positives from Endogenous Claudins | CLDN6-specific siRNA Set for target engagement validation |
Live CLDN6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CLDN6-targeted therapy field is rapidly maturing from preclinical validation to clinical execution. With BioNTech's BNT211 CAR-T advancing into Phase II and Astellas' ADC program demonstrating preliminary efficacy, the competitive landscape is bifurcating between cellular therapies and antibody-conjugate modalities. A critical inflection point has emerged around target specificity, as the highly homologous CLDN9 presents significant safety liabilities, driving demand for exquisite selectivity screening tools. As first-generation therapies reach the clinic, the next wave of R&D is targeting CLDN6/CLDN9 bispecific discrimination and combination strategies with PD-1 inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T Cell Therapy | BioNTech (BNT211), Autolus | Ovarian, Testicular Cancer | Cell surface expression stability (Need high-titer Lentivirus for K562/CHO line construction) |
| ADC | Astellas (AS2693), Daiichi Sankyo | Solid Tumors (Gastric, Lung) | Internalization Rate & CLDN9 Selectivity (Need Full-length CLDN6/CLDN9 stable cell lines) |
| Bispecific Antibodies | Amgen (AMG 199), Lava Therapeutics | Gastric, Lung Cancer | Homology Discrimination (Need CLDN6/CLDN9 Ortholog Protein Pair) |